2022-12-02

Clinical Lab Products: The Future of Cervical Cancer Screening is Here

Molly Broache, Associate Director, Medical Affairs for US IDS discusses the future of cervical cancer screening

The future of cervical cancer screening is here. Featured in Clinical Lab Products, Associate Director of Medical Affairs Molly Broache notes that in today’s world where patients are catching up on missed screenings, adding pressure on already-pressured labs, it’s that much more important to take advantage of instruments and assays that do more and do better. The BD Onclarity HPV Assay is a perfect example with its cutting-edge approach to HPV testing.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

Doctor giving patient brochure
Cervical Cancer | News & Updates
Press Release: New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer
BD blog: The future of cervical cancer screening: More genotypes means more precise care
Cervical Cancer | News & Updates
BD blog: The future of cervical cancer screening: More genotypes means more precise care
Fast Company op-ed
Cervical Cancer | News & Updates
POV: The U.S. healthcare system is failing Black and Latina women